GlassScriptPhysician profile
David Cole Dyslin
NPI 1720051212
$5,349.00
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,888 · 2020: $51.22 · 2021: $19.35 · 2022: $163 · 2023: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,576 · Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,575.82 |
| Food and Beverage | $651.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $2,241.85 | 2019-2023 | Gore Bio-A Tissue Reinforcement, Seamguard, Balloon Sheath With Dilator |
| Medical Device Business Services, INC. | $1,672.09 | 2019 | |
| Intuitive Surgical, INC. | $545.93 | 2019-2022 | |
| Ethicon US, LLC | $305.86 | 2019-2022 | |
| Karl Storz Endoscopy-America | $232.21 | 2019-2022 | |
| Davol INC. | $144.61 | 2019 | |
| Covidien LP | $70.92 | 2019 | |
| Shire North American Group INC | $32.43 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2019 | |
| Olympus America INC. | $17.87 | 2019 | |
| Endo Pharmaceuticals INC. | $17.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2020 | |
| Aesculap, INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dyslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.